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Next generation sequencing and association studies <p>Human sequence generated from three next-generation sequencing platforms reveals systematic variability in sequence coverage due  to local sequence characteristics.</p>
Abstract
Background:  Next generation sequencing (NGS) platforms are currently being utilized for
targeted sequencing of candidate genes or genomic intervals to perform sequence-based
association studies. To evaluate these platforms for this application, we analyzed human sequence
generated by the Roche 454, Illumina GA, and the ABI SOLiD technologies for the same 260 kb in
four individuals.
Results: Local sequence characteristics contribute to systematic variability in sequence coverage
(>100-fold difference in per-base coverage), resulting in patterns for each NGS technology that are
highly correlated between samples. A comparison of the base calls to 88 kb of overlapping ABI
3730xL Sanger sequence generated for the same samples showed that the NGS platforms all have
high sensitivity, identifying >95% of variant sites. At high coverage, depth base calling errors are
systematic, resulting from local sequence contexts; as the coverage is lowered additional 'random
sampling' errors in base calling occur.
Conclusions: Our study provides important insights into systematic biases and data variability that
need to be considered when utilizing NGS platforms for population targeted sequencing studies.
Background
The Sanger method [1] of sequencing by capillary electro-
phoresis using the ABI 3730xL platform has been employed
in many historically significant large-scale sequencing
projects and is considered the 'gold standard' in terms of both
read length and sequencing accuracy [2]. Several next gener-
ation sequencing (NGS) technologies have recently emerged,
including Roche 454, Illumina GA, and ABI SOLiD, which are
able to generate three to four orders of magnitude more
sequence and are considerably less expensive than the Sanger
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method on the ABI 3730xL platform (hereafter referred to as
ABI Sanger) [2-4]. To date these new technologies have been
successfully applied toward ChIP-sequencing to identify
binding sites of DNA-associated proteins [5,6], RNA-
sequencing to profile the mammalian transcriptome [7,8], as
well as whole human genome sequencing [9-11]. Currently
there is much interest in applying NGS platforms for targeted
sequencing of specific candidate genes, intervals identified
through single nucleotide polymorphism (SNP)-based associ-
ation studies, or the entire human exome [12-15] in large
numbers of individuals.
As population targeted sequencing studies are initiated, it is
important to determine the issues that will be encountered in
generating and analyzing data produced by NGS platforms
for this application. Here, we generate 260 kb of targeted
sequence in four samples using the manufacturer recom-
mended and/or supplied sample library preparation meth-
ods, sequence generation, alignment tools, and base calling
algorithms for the Roche 454, Illumina GA, and ABI SOLiD
platforms (Figure 1). For each NGS technology we generated
a saturating level of redundant sequence coverage, meaning
that increased coverage is likely to have minimal, if any, effect
on data quality and variant calling accuracies. We analyzed
the sequences produced by each platform for per-base
Overview of experimental design Figure 1
Overview of experimental design. Six genomic intervals, each encoding genes for K+/Na+ voltage-gated channel proteins, were amplified using DNA from 
four individuals and LR-PCR reactions to generate 260 kb of target sequence per sample. Amplicons from each individual were pooled in equimolar 
amounts and then sequenced using the three NGS platforms. The 260 kb examined in this study is representative of human sequences containing 38% 
repeats and 4% coding sequence compared with 47% and 1%, respectively, genome-wide. For each sample 88 kb was amplified using short range PCR (SR-
PCR) reactions targeting the exons and evolutionarily conserved intronic regions. Each SR-PCR amplicon was individually sequenced in the forward and 
reverse directions using the ABI-3730xL platform (Additional data file 2). Data generated from the NGS platforms were analyzed to identify bases variants 
from the reference sequence (build 36) and the quality of the variant calls was assessed using platform specific methodologies. A comparative analysis of 
the sequence data from the NGS platforms and ABI Sanger was then performed to determine accuracy, and false positive and false negative rates.
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sequence coverage and for systematic biases giving rise to low
coverage. We show that each NGS platform generates its own
unique pattern of biased sequence coverage that is consistent
between samples. For the short-read platforms, low coverage
intervals tend to be in AT-rich repetitive sequences. We also
performed a comparative analysis with sequence generated
by the well-established ABI Sanger platform (Figure 1) to
determine base calling accuracies and how average fold
sequence coverage impacts base calling errors. Although the
three NGS technologies correctly identify >95% of variant
alleles, the average sequence coverage required to achieve
this performance is greater than the targeted levels of most
current studies.
Results
Generation and alignment of sequence reads to 
targeted intervals
The targeted sequence was amplified in the four DNA sam-
ples using long-range PCR (LR-PCR) reactions that were
combined in equimolar amounts and sequenced using the
three NGS technologies (Figure 1). For the Roche 454 plat-
form we obtained an average of 49,000 reads per sample with
an average length of 245 bp (Supplemental Table 1 in Addi-
tional data file 1), using Illumina GA we generated an average
of 5.9 million reads each 36 bases in length per sample, and
using ABI SOLiD we obtained an average of 19.7 million reads
each 35 bases in length per sample. Thus, the amount of
sequence data generated and analyzed was dependent on the
NGS platform and the fraction of the run that was utilized.
The NGS technologies generate a large amount of sequence
but, for the platforms that produce short-sequence reads,
greater than half of this sequence is not usable. On average,
55% of the Illumina GA reads pass quality filters, of which
approximately 77% align to the reference sequence (Supple-
mental Table 1 in Additional data file 1; Additional data file 2).
For ABI SOLiD, approximately 35% of the reads pass quality
filters, and subsequently 96% of the filtered reads align to the
reference sequence. Thus, only 43% and 34% of the Illumina
GA and ABI SOLiD raw reads, respectively, are usable. In con-
trast to the platforms generating short-read lengths, approxi-
mately 95% of the Roche 454 reads uniquely align to the
target sequence. When designing experiments and calculat-
ing the target coverage for a region, one must consider the
fraction of alignable sequence.
Overrepresentation of amplicon end sequences
In examining the distribution of mapped reads, we observed
that the sequences corresponding to the 50 bp at the ends and
the overlapping intervals of the amplicons have extremely
high coverage (Figure 2; Additional data file 2). These
regions, representing about 2.3% (approximately 6 kb) of the
targeted intervals, account for up to 56% of the sequenced
base pairs for Illumina GA technology. This extreme sequence
coverage bias results from overrepresentation of the ampli-
con ends in the DNA samples after fragmentation prior to
library generation. For the ABI SOLiD platform an amplicon
end depletion protocol was employed to remove the overrep-
resented amplicon ends; this was partially successful and
resulted in the ends accounting for up to 11% of the sequenced
base pairs. For the Roche 454 technology, overrepresentation
of amplicon ends versus internal bases is substantially less,
with the ends composing only 5% of the total sequenced
bases; this is likely due to library preparation process differ-
ences between Roche 454 and the short-read length plat-
forms. The overrepresentation of amplicon end sequences is
not only wasteful for the sequencing yield but also decreases
the expected average coverage depth across the targeted
intervals. Therefore, to accurately assess the consequences of
sequence coverage on data quality, we removed the 50 bp at
the ends of the amplicons from subsequent analyses.
Sequence coverage of targeted intervals
For each platform we generated a saturating level of redun-
dant sequence coverage, meaning that increased coverage is
likely to have minimal, if any, effect on data quality. For the
four samples the average sequence coverage depth across the
analyzed base pairs is 43×, 188×, and 841× for Roche 454,
Illumina GA, and ABI SOLiD, respectively (Supplemental
Table 2 in Additional data file 1). For all three NGS technolo-
gies there is greater than a hundred-fold variation in the per-
base sequence coverage depth (Figure 2). We performed sev-
eral analyses to determine if the sample preparation method
and/or a specific class of sequence elements were responsible
for the observed variability (Additional data file 2). We first
tested whether the large variability resulted from pooling of
the amplicons. For 90% of the amplicons the fold difference
in average coverage of unique sequences is less than 2.46,
2.72, and 2.99 on the Roche 454, Illumina GA and ABI SOLiD
platforms, respectively (Supplemental Table 3 in Additional
data file 1), showing that the error in equimolar pooling or
amplicon specific bias (sequence, length) explains only a
small fraction of the observed coverage variability. Next we
examined how the sequence coverage differs within the indi-
vidual amplicons. For Roche 454, Illumina GA, and ABI
SOLiD the average coefficient of variance was 0.33, 0.9, and
0.73, respectively, for all base pairs, and 0.35, 0.84 and 0.76,
respectively, when restricted to unique non-repetitive
sequence, defined here as not present in the RepBase data-
base [16]. These results indicate that unique sequences
present at equimolar amounts in the library generation step
end up being covered at vastly different read depths.
It is important to consider how well the NGS technologies are
able to generate sequence reads containing repetitive ele-
ments as these sequences comprise approximately 45% of the
human genome and may potentially impact genome function.
Compared to unique sequences, the Roche 454 technology
has a 1.25-fold overrepresentation of LINE elements, Illu-
mina GA has greater than 2-fold higher coverage of SINEs,
Alus and simple repeats, while for ABI SOLiD all repetitivehttp://genomebiology.com/2009/10/3/R32 Genome Biology 2009,     Volume 10, Issue 3, Article R32       Harismendy et al. R32.4
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Non-uniform per-base sequence coverage Figure 2
Non-uniform per-base sequence coverage. The 100-kb interval on chromosome 3 encoding the SCN5A gene (blue rectangles and joining lines) was 
amplified using eight LR-PCR amplicons (red filled rectangles in upper panel). On the y-axis, the fold sequence coverage scale is shown for each platform. 
The upper panel shows that amplicon end sequences are highly overrepresented. The y-axis was set to show the relative fold coverage of the sequences in 
the interval and therefore does not accurately represent the maximum fold coverage of the amplicon ends, which was 311, 195,473, and 15,041 for Roche 
454, Illumina GA, and ABI SOLiD, respectively, in the sample shown. The lower panel shows the non-uniformity of sequence coverage across an 
approximately 17-kb region encompassing four exons of SCN5A. The locations of the repetitive elements (lower black/gray rectangles) in the interval are 
shown.http://genomebiology.com/2009/10/3/R32 Genome Biology 2009,     Volume 10, Issue 3, Article R32       Harismendy et al. R32.5
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elements are covered at approximately half the fold coverage
of unique sequences (Supplemental Table 4 in Additional
data file 1). Thus, considering all three NGS platforms, Roche
454 generates the most even coverage across both unique and
repetitive sequences, Illumina GA shows the most variability
in coverage, and ABI SOLiD demonstrates a strong bias
against coverage of repetitive elements.
Interestingly, each NGS technology has a unique reproduci-
ble pattern of non-uniform sequence coverage: sequences
with high or low coverage in one sample typically had high or
low coverage in the other three samples (Figure 3). The coef-
ficient of correlation (r) of per-base sequence coverage depth
was 0.62, 0.90, and 0.88 between samples on Roche 454,
Illumina GA, and ABI SOLiD, respectively. On the other
hand, per-base sequence coverage depth for the same sample
on different platforms was not well correlated (r  < 0.19).
These data indicate that for all three NGS technologies local
sequence characteristics substantially contribute to the
observed variability in coverage unique to each technology.
To gain insight into systematic biases of each NGS technol-
ogy, we examined the sequence composition of intervals with
no or low coverage (defined as less than 5% of the average
coverage depth; Additional data file 2). Despite having con-
siderably higher average sequence coverage, the ABI SOLiD
data have the largest number of no and low coverage intervals
(spanning 464 bp and 3,415 bp respectively), the majority of
which are AT-rich repetitive sequences (Supplemental Tables
5 and 6 in Additional data file 1). The Illumina GA low cover-
age regions (spanning 272 bp) also tend to be AT-rich repeti-
tive sequences. Overall, for the short read platforms read
depth coverage decreases with increasing AT content, which
is consistent with previous studies [17,18] (Supplemental Fig-
ure 1 in Additional data file 3). Roche 454 had one no and one
low coverage interval (spanning 4 bp and 59 bp, respectively).
Detection of single nucleotide base variants
We established parameters for calling variant bases in the
sequence generated by the NGS technologies based on opti-
mized concordance with the variant calls in the ABI Sanger
data. As previously observed, PCR sample preparation can
produce imbalanced amplification of the two alleles for some
amplicons, resulting in incorrect genotype calls at variant
bases by specifically calling heterozygous sites as
homozygous sites [19]. Imbalanced amplification is usually
suspected to result from polymorphisms in or near the oligo-
nucleotide priming sites that result in greater efficiency of
amplification for one of the alleles. To measure this phenom-
enon in our sample preparation method, we looked at the
alternate allele read frequency (AARF; Additional data file 2)
at ABI Sanger identified heterozygous positions in the
sequence data for the three NGS platforms. Out of the 28
amplicons in this study, four demonstrated allelic imbalances
in amplification for one or more samples (Supplemental
Table 7 in Additional data file 1). We removed the sequence
Each NGS technology generates a consistent pattern of non-uniform sequence coverage Figure 3
Each NGS technology generates a consistent pattern of non-uniform sequence coverage. (a) Sequence coverage depth is displayed as a gray-scale (0-100× 
for Roche 454; 0-500× for Illumina GA and ABI SOLiD) along an approximately 25-kb region of chromosome 11 amplified by three long-range PCR 
products (red rectangles). (b) A heat-map colored matrix displays the coefficient of correlation of coverage across the entire 260 kb of analyzed sequence 
between each of the 72 possible pair-wise comparisons (four samples by three technologies). The apparent lower correlation of the Roche-454 sequence 
coverage is more reflective of the smaller amplitude in the coverage variability (lower average coefficient of variance) than a lack of coverage correlation 
from sample to sample. The correlation of NA17460 with the other three samples on the ABI SOLiD platform is slightly lower due to technological issues 
(Additional data file 2) and was therefore excluded from the coefficient of correlation calculation reported in the text.http://genomebiology.com/2009/10/3/R32 Genome Biology 2009,     Volume 10, Issue 3, Article R32       Harismendy et al. R32.6
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data for these four amplicons from the variant quality analy-
sis so as to focus on errors caused by the NGS platforms and
thereby not have the analysis confounded by sample prepara-
tion issues.
Accuracy of sequence variant calls compared to 
microarray genotype calls
Accuracy of the variant calls in the NGS and ABI Sanger data
for the four samples was initially assessed by comparison to
genotype calls for approximately 80 SNPs located in the
sequenced intervals and assayed by the Illumina Hap550
BeadChip. The genotype accuracy of the four platforms is
97.4%, 100%, 99.7%, and 98% for Roche 454, Illumina GA,
ABI SOLiD and ABI Sanger, respectively (Supplemental
Tables 8 and 9 in Additional data file 1). These data show a
greater number of discordant genotypes for Roche 454. It is
important to note that comparison between sequence and
SNPs genotyped on commercial arrays is not expected to be
fully indicative of NGS platform variant base calling accuracy
in genomic sequences at large. First, false positive rates can-
not be considered by SNP microarray technologies because
novel variants are not detected. Second, SNP microarrays
typically query a subset of 'well behaved' bases; hence, false
negative rates based on microarray technology can be under-
estimated.
Variant detection comparing NGS to ABI Sanger
To further assess sequence quality, we next performed a four-
way comparison of the base calls generated from the three
NGS technologies and ABI Sanger. The identification of het-
erozygous and homozygous alternate loci was performed in
258,879 base pairs analyzed from all four samples (Supple-
mental Table 10 in Additional data file 1). There were twenty
loci for which the three NGS technologies were concordant in
their base calls but discordant with the ABI Sanger calls. Vis-
ual inspection of the ABI Sanger traces revealed that eight of
these loci represented base calling errors in the original data,
thereby resolving the discrepancy. However, for 12 loci (9
false positive and 3 false negative calls) the discrepancies
were not resolved (Figure 4g,h). Two of the discrepant calls
were assayed by the Illumina Hap550 array (Supplemental
Table 9 in Additional data file 1) and their calls were concord-
ant with the NGS platforms. We examined the genotypes of
the remaining discrepant calls by independent Sanger
sequencing. As previously established [19,20], errors in
Sanger sequencing of human diploid DNA are approximately
7% and result from: PCR primers sometimes overlapping
unknown DNA variants leading to imbalanced amplification
of the two alleles; and difficulty of automated software to cor-
rectly call heterozygous sites. Thus, replicating the Sanger
sequencing with different PCR and sequencing primers and
manual inspection of the traces can be considered an inde-
pendent measurement. We successfully examined eight of the
discrepant calls using this approach, of which seven agreed
with the calls made by the NGS platforms (Supplemental Fig-
ure 3 in Additional data file 3). In total, nine of the ten dis-
crepant calls investigated (two by genotyping and seven by
Sanger sequencing) were confirmed as being incorrect in the
original ABI-Sanger sequencing. As a result of this analysis
for the first time by comparison with NGS technologies, the
ABI Sanger false positive and false negative rates for human
diploid DNA are estimated to be approximately 0.9% and
approximately 3.1%, respectively. These 12 loci identified as
ABI Sanger errors were removed from consideration when
assessing the NGS technologies' performance.
W e  n e x t  c a l c u l a t e d  f i v e  d i fferent performance metrics
(sequencing accuracy, variant accuracy, false positive rate,
false negative rate, and variant discrepancy rate) for the NGS
platforms (Supplemental Table 11 in Additional data file 1).
Sequencing accuracy, which measures the concordance of all
calls including homozygous reference, was greater than
99.99% for all NGS technologies (Figure 4a). On the other
hand, variant accuracy, which measures the ability of NGS
technologies to make a correct call at known variant positions
identified by ABI Sanger, was lower, averaging over the four
individuals for each technology at 95%, 100%, and 96% for
Roche 454, Illumina GA, ABI SOLiD, respectively (Figure 4b).
The false positive rate of Roche 454, Illumina GA and ABI
SOLiD is approximately 2.5%, approximately 6.3%, and
approximately 7.8%, respectively; the false negative rates are
approximately 3.1%, approximately 0%, and 0.9% (Figure
4d,e). We also examined the variant discrepancy rates, which
reflect the number of positions that have been correctly iden-
tified as variant, but assigned incorrect zygosity. For Roche
454, Illumina GA, and ABI SOLiD the variant discrepancy
rates were 2%, 0%, and 3%, respectively. These five perform-
ance metrics indicate that at saturating sequence coverage
and the methodologies employed to call variants, the short-
read platforms have greater sensitivity but lower specificity
than Roche 454.
In examining the sequences underlying false positive and
false negative calls in the NGS technologies, we determined
that these errors were unexpectedly not associated with low
sequence coverage but rather are the result of systematic
biases (Figure 4g,h,i). For each NGS platform, 47% of the
bases with an error in one sample had an error in at least one
other sample (Supplemental Table 12 in Additional data file
1). Greater than 72% of these false positive and negative calls
are associated with at least one and >33% with two of the fol-
lowing sequence contexts: repetitive elements; a homopoly-
mer stretch ≥6 bases; simple repeats; the presence of an indel
within 30 bp. These sequence contexts likely present signifi-
cant challenges during read alignment, especially for the
short-read technologies, resulting in variant detection errors.
Two out of the three false negatives specific for the ABI SOLiD
platform were due to the inability to detect adjacent SNPs
with existing variant calling software applied to color-space
sequencing technology (Additional data file 2).http://genomebiology.com/2009/10/3/R32 Genome Biology 2009,     Volume 10, Issue 3, Article R32       Harismendy et al. R32.7
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Performance metrics of NGS technologies Figure 4
Performance metrics of NGS technologies. (a-f) Error bars represent minimum and maximum values obtained from the four samples. (g-i) Venn diagram 
representation of false positive calls (g), false negative calls (h) and discrepant variants calls (i). The inset caption displays the color-coding of each NGS 
technology and overlaps: for Roche 454 (red), Illumina GA (yellow) and ABI SOLiD (blue). For each NGS platform the number of base calls with errors 
associated with specific sequence contexts is given (repeat = repetitive element). When two sequence contexts are present they are both listed.http://genomebiology.com/2009/10/3/R32 Genome Biology 2009,     Volume 10, Issue 3, Article R32       Harismendy et al. R32.8
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Detection of indels
Detection of heterozygous indels remains a technological
challenge using the ABI Sanger platform [21]. Here the ABI
Sanger sequencing detected 11 heterozygous indels in the 88
kb of sequence analyzed. The Roche 454 technology success-
fully identified five of these indels, all of which ranged from 3-
16 bp in length (Supplemental Table 13 in Additional data file
1). Of the six indels missed by Roche 454, five were single base
in length in homopolymer sequences, and one was a 15 bp
insertion that was not completely resolved due to low cover-
age. Interestingly, Roche 454 identified 43 additional indels
in the 88 kb of overlapping ABI Sanger sequences (Supple-
mental Table 14 in Additional data file 1). Bearing in mind
that the false positive rate for these data cannot be estimated,
this suggests that the Roche 454 platform may be more useful
for identifying indels than the ABI Sanger technology. The
Illumina GA and ABI SOLiD platforms at the time of this
analysis were unable to identify indels automatically.
Assessing performance metrics at lower coverage
To efficiently perform population-based targeted sequencing
studies using NGS technologies, it is important to determine
the lowest average sequence coverage required to achieve a
specified sensitivity and specificity. To estimate this coverage
requirement, we simulated varying coverage depths for all
three technologies, recalled genotypes, and calculated false
positive and false negative rates for each coverage depth
(Additional data file 2). The maximum simulated average
coverage was 40-fold for Roche 454 and 140-fold for both
Illumina GA and ABI SOLiD. The false positive error rates are
more impacted by low coverage compared with false negative
rates; thus, we focused our analysis on the former. The aver-
age coverage depth for 50% false positive error rate degrada-
tion (percentage of the minimum simulated error rate; see
Materials and methods) is achieved at 25-fold, 68-fold, and
39-fold and for 10% degradation at 34-fold, 110-fold and 101-
fold for Roche 454, Illumina GA, and ABI SOLiD, respectively
(Figure 5). These results indicate that the short-read technol-
ogies have a two- to three-fold greater sequence coverage
depth requirement relative to Roche 454. Thus, errors at high
coverage are systematic and typically associated with specific
sequence contexts; at lower coverage errors result from ran-
dom sampling in base calling. Consistent with this observa-
tion, the performance of the NGS technologies at low
sequence coverage is correlated with per-base sequence cov-
erage uniformity; the Illumina GA, which has the highest cov-
erage variability, performs the worst at lower coverage,
whereas Roche 454, with the most uniform coverage, per-
forms the best. This observation suggests that for all the NGS
technologies, achieving more uniform sequence coverage
would result in considerably higher performance at lower
coverage.
Discussion
Our study highlights many issues encountered as NGS plat-
forms are utilized for population-based targeted sequencing
studies, including biases in sample library generation, diffi-
culties mapping short reads, variation in sequence coverage
depth of unique and repetitive elements, difficulties detecting
indels with short reads, the systematic errors of the NGS tech-
nologies and the impact of all these features on variant calling
accuracy. We note that the results of our analyses reported for
each NGS platform are the combined effects of the manufac-
turer recommended laboratory methods, sequence read
alignment tools, and base calling algorithms utilized.
False positive rates (FPRs) and false negative rates for the three NGS technologies at simulated varying coverage depths Figure 5
False positive rates (FPRs) and false negative rates for the three NGS technologies at simulated varying coverage depths. Performances of (a) Roche 454, 
(b) Illumina GA, and (c) ABI SOLiD at lower coverage depths were simulated by random subsampling of the reads. Error bars represent the standard 
deviation over the four samples for ten iterations. The thresholds for a 10% and 50% error rate degradation of the minimum false positive rate are 
indicated by dashed and dotted lines, respectively, and the corresponding coverage depth reported in dashed and dotted boxes, respectively.http://genomebiology.com/2009/10/3/R32 Genome Biology 2009,     Volume 10, Issue 3, Article R32       Harismendy et al. R32.9
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At high sequence coverage all NGS platforms have excellent
variant calling accuracy (>95%) as assessed by the detection
of known SNP variants. However, this accuracy is lower than
the values typically stated for the NGS platforms [22-25].
NGS-reported accuracies are typically being measured, in
human sequences, by comparison to commercial SNP geno-
typing arrays, which we demonstrate are inadequate for
ascertaining false positive and false negative rates. Therefore,
the sequence-based accuracies reported here are likely to be
more indicative of the real performance of NGS platforms for
de novo detection of variants in human sequences.
Interestingly, our analysis indicates that ABI Sanger has a
false negative rate of approximately 3%, which is comparable
to the three NGS technologies at saturating coverage. Thus,
there are likely many more DNA polymorphisms yet to be
detected in human samples [26]. Indeed, heterozygous indel
detection, which is difficult using PCR-based sample prepara-
tion methods and ABI Sanger sequencing [27], may be easier
to achieve using NGS platforms because each allele is
sequenced and detected independently. This is especially
important since indel variants constitute approximately 25%
of the reported mutations implicated in human disease [28]
and their identification would precede a more complete
understanding of how they determine human phenotypes.
The saturating sequencing coverage we exploited enabled the
determination of the sequence coverage threshold below
which false discovery rates of variants were unacceptably
high. This revealed that for accurate detection of biallelic
sites, the average depth of sequence coverage required for all
three NGS platforms but especially for the short-read tech-
nologies is considerably higher than the empirically deter-
mined coverage of 20-fold utilizing random Sanger
sequencing [29]. This coverage requirement for NGS technol-
ogies is further supported by a recent multiplexed targeted
resequencing study that showed that accurate detection of
variant loci necessitates a 20-fold read depth per base, and a
higher average depth due to coverage variability [30], and a
recent yeast mutational profiling study that showed 10-15-
fold coverage is required to detect variants in haploid organ-
isms [31]. Importantly, these required average sequence cov-
erages are much higher than what is typically employed in
targeted sequencing studies utilizing NGS technologies.
Conclusions
Our results suggest that to effectively balance cost and data
quality for population targeted sequencing studies, there are
two key aspects of NGS technologies that need optimization:
t h e  u n i f o r m i t y  o f  p e r - b a s e  s e q u e n c e  c o v e r a g e  m u s t  b e
improved to reduce the total amount of sequence generation
required; and the systematic errors that impact variant call-
ing accuracy need to be reduced so that the false positive and
false negative rates are acceptable for sequence-based associ-
ation studies. Although recent improvements in the NGS
platforms, such as paired end and longer reads, will mitigate
these issues, all aspects of the NGS platforms, laboratory
methods, sequence alignment tools, and base calling algo-
rithms partially contribute to the problems and, therefore,
need to be simultaneously optimized.
Materials and methods
Sample preparation
Twenty-eight LR-PCR reactions were performed to amplify
six genomic intervals spanning a total of 266 kb in each of
four DNA samples (NA17275, NA17460, NA17156, and
NA17773) obtained from the Coriell Institute [32] (Additional
data file 2). Following LR-PCR, the 28 amplicons generated
using a single DNA sample template, ranging in size from
3,088 bp to 14,477 bp, were quantified, combined in equimo-
lar amounts, and used to create libraries for Roche 454, Illu-
mina GA and ABI SOLiD sequencing.
Roche 454
The Roche 454 laboratory methods and protocols used were
as described by Rothberg and coworkers [23]. The reads pro-
duced by the Roche 454 FLX platform were mapped to the
reference sequence using the algorithm Newbler version
1.1.03.19 (provided by Roche), unless stated otherwise.
Illumina GA
The Illumina GA libraries were prepared according to the
manufacturer's instructions from the 28 equimolar pooled
PCR products except for the fragmentation step (Additional
data file 2). The Illumina GA reads were aligned with MAQ
0.6.2 [33], unless stated otherwise.
ABI SOLiD
Long mate pair (LMP) libraries DNA libraries were generated
from the four 28 equimolar pooled amplicon samples and end
sequenced using standard ABI SOLiD protocols at Applied
Biosystems in Beverly, MA. For each sample, ABI aligned the
sequence reads to the reference sequence and mate-pairing
information was not employed in this project. The aligned
reads and the number of calls per base for each position were
used for data analysis (Additional data file 2).
The LMP library construction process requires more DNA
amplification and manipulation and is useful for the detec-
tion of indels and structural variants. Therefore, as opposed
to the library construction processes for Roche-454 and Illu-
mina GA, which were focused on read fragment preparation
alone, discarding mate-pair information from the LMP proto-
col reads and using them as unpaired reads may have intro-
duced mapping biases when used to detect SNPs. Indeed, the
generation of these libraries creates variable tag lengths that
require different mapping techniques to ensure proper repre-
sentation of the genome. Shorter tags will not map with a 35
bp and 3 mismatches schema and as a result substantial por-http://genomebiology.com/2009/10/3/R32 Genome Biology 2009,     Volume 10, Issue 3, Article R32       Harismendy et al. R32.10
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tions of the genome can be differentially sampled due to fixed
mapping criteria.
These differences in the library techniques emphasize the
need for the use of quality score information in the ABI SOLiD
reads to properly trim the data before mapping and allow for
proper comparison to a Roche 454 and Illumina GA data that
currently perform Keypass, Chastity and Purity filtering of
the data before SNP calling.
Calling genotypes in the NGS sequence data
We define the alternate allele as the most commonly called
base (which is not the reference base) for a given position in
the reference sequence. Then, the AARF is the fraction of
reads corresponding to the alternate allele.
Positions called as reference homozygote by ABI Sanger have
AARFs close to 0% by the NGS technologies (Supplemental
Figure 2 in Additional data file 3). Also, positions called as
alternate homozygous by ABI Sanger have AARFs near or at
100% by the NGS technologies. The AARFs for heterozygous
calls by ABI Sanger is centered at 50% for Roche 454 and Illu-
mina GA; for ABI SOLiD it is centered at 42% (Additional
data file 2). Upon independent inspection of the three tech-
nologies, most ABI Sanger-called heterozygotes fell in the
range 20-80%. Thus, for the NGS technologies, utilizing only
high quality bases we call positions with AARFs between 20%
and 80% as heterozygous, positions with AARFs >80% as
homozygous alternate, and positions with AARFs <20% as
homozygous reference (Additional data file 2).
Short-range PCR and Sanger sequencing
We used an existing data set deposited by JCVI and per-
formed under the auspices of the National Heart, Lung and
Blood Re-sequencing and Genotyping program [34]. The data
set included 88 kb of non-contiguous sequence encompassing
the exons and the intronic sequence conserved with mouse
and rat in the K+/Na+ channel proteins produced by employ-
ing 273 short-range PCR reactions generating amplicons
averaging 418 bp in length.
Definitions of performance metrics
In order to assess the performance of the sequencing technol-
ogies, we define several metrics.
Comparing a genotyping microarray to a sequencing technology
Genotype accuracy
We genotyped the four samples on the Illumina Hap550
microarray according to specifications of the manufacturer.
We compared the genotype calls of the SNPs on the Hap550
microarray with the genotypes observed from sequencing
(Supplemental Table 8 in Additional data file 1). Genotype
accuracy is defined as: (Number of genotypes matching
exactly between Illumina Hap550 and a sequencing technol-
ogy)/(Number of compared positions).
Metrics for comparing a NGS sequencing technology with ABI Sanger
We initially assumed the ABI Sanger sequence data are cor-
rect because it is an established method with the longest his-
tory [2]. Upon further analysis, we found that this assumption
was not always true; there were some positions incorrectly
called by ABI Sanger, but correctly called by the NGS technol-
ogies (see Results). We refer to Table 1 annotations to clarify
these definitions.
Sequencing accuracy
This is defined as the number of concordant calls between
ABI Sanger and a NGS technology. Following the diagram
above, this is calculated as (A1 + B2 + C3)/Total, where Total
is defined as the number of positions with genotype calls by
both technologies, or (A1 + A2 + A3 + B1 + B2 + B3 + C1 + C2
+ C3). Because the sequencing accuracy metric is dominated
by the concordance of a large number of homozygous refer-
ence calls (A1), this metric tends to be very near 1.
Variant accuracy
Because 'sequencing accuracy' tends to be dominated by the
large number of homozygous reference calls, we define
another metric called 'variant accuracy'. Variant accuracy is
restricted to the variant positions called by ABI Sanger and is
defined as: (B2 + C3)/(A2 +A3 + B2 + B3 + C2 + C3).
Table 1
Annotations of the genotypes differences to illustrate the definition of the metrics used to compare ABI Sanger and NGS Technologies
Sanger
NGS technology Homozygous reference Heterozygous Homozygous alternate N/N
Homozygous reference A1 A2 A3 A4
Heterozygous B1 B2 B3 B4
Homozygous alternate C1 C2 C3 C4
N/N D1 D2 D3 D4
N/N: positions at which genotype was not called.http://genomebiology.com/2009/10/3/R32 Genome Biology 2009,     Volume 10, Issue 3, Article R32       Harismendy et al. R32.11
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False positive rate of variants (false positive rate)
We define a false positive when the NGS technology calls a
variant where ABI Sanger calls a homozygous reference. The
false positive rate is calculated as (B1 + C1)/(B1 + B2 + B3 +
C1 + C2+ C3).
False negative rate of variants (false negative rate)
We define a false negative when ABI Sanger detects a variant,
but the NGS method calls this locus as a homozygous refer-
ence. The false negative rate is calculated as (A2 + A3)/(A2 +
A3 + B2 + B3 + C2 + C3).
Variant discrepancy rate
We define the variant discrepancy rate as (B3 + C2)/(B2 + B3
+ C2 + C3). This metric reflects ABI Sanger variant positions
that are also detected by the NGS technology, but where the
genotype calls disagree.
Coverage rate
The fraction of positions with genotype calls is defined as 1-
(D1 + D2 + D3)/(A1 + A2 + A3 + B1 + B2 + B3 + C1 + C2 + C3
+ D1 + D2 + D3).
ABI Sanger false positive rate
We define a ABI Sanger false positive when ABI Sanger calls
a variant but all three NGS technologies call the locus as
homozygous reference. We assume the NGS technologies to
be correct, and this was confirmed by re-inspection of the ABI
Sanger traces. The ABI Sanger false positive rate is calculated
as follows. The numerator is the number of loci that are called
as homozygous reference by all three NGS technologies, but
as a variant in ABI Sanger. In the denominator, we consider
all positions that were called as variant by Sanger and also
had a genotype call by all three NGS technologies.
ABI Sanger false negative rate
We define a ABI Sanger false negative as a locus where the ini-
tial call by ABI Sanger is homozygous reference but all three
NGS technologies detect a variant at this locus. In the numer-
ator of the ABI Sanger false negative rate, we count the
number of variant loci that are identified by all three NGS
technologies but called as homozygous reference by ABI
Sanger. We note that zygosity may not agree among the three
NGS technologies, but if all three technologies identify a var-
iant at the position, the locus is included (Supplemental Table
12 in Additional data file 1). The denominator represents the
number of loci called as variant by all three NGS technologies
(although the zygosity may differ).
Validation of genotypes discordant between ABI 
Sanger and the three NGS platforms
PCR reactions were performed in 50 μl platinum buffer (Inv-
itrogen, Carlsbad, CA, USA) using 5 pM of primers (Supple-
mental Table 15 in Additional data file 1) and 0.2 μl of
platinum Taq DNA polymerase, incubated 2 minutes at 94°C
followed by 35 cycles at 30 s at 94°C, 30 s at 60°C and 30 s at
72°C, followed by 5 minutes at 72°C for final elongation. PCR
products were purified using QIAquick PCR purification col-
umns (Qiagen, Hilden, Germany)) and sequenced in both
directions using the same primers as in the PCR and Big Dye
terminator sequencing chemistry (Applied Biosystems, Fos-
ter City, CA USA).
Simulations
Simulations were performed in order to assess performance
of each NGS platform at lower coverage depths. For each sim-
ulation, we randomly sampled a subset of the reads and
recalled genotypes. The size of the subset was determined by
the desired coverage depth.
Inferring coverage at various error rate degradations
To obtain the coverage depths in Figure 5, we first examined
the error rate at the maximal simulated coverage. For 50%
error rate degradation, we multiplied the error rate at the
maximal coverage by 1.5 to get the desired error rate. For 10%
error rate degradation, we multiplied the error rate at the
maximal coverage by 1.1 to get the desired error rate. We then
examined the error rates from the simulations at different
coverage depths, and interpolated what coverage depth corre-
sponds to the desired error rate. For example, the false posi-
tive error rate for Illumina GA at 140× from the simulations
is 0.073. At 50% error rate degradation, the false positive rate
is 0.110. The false positive rates at coverage depths of 60× and
80× are 0.118 and 0.099, respectively, so we know that a cov-
erage depth within the range of 60× to 80× will give a false
positive rate of 0.110. Using linear interpolation, we deduce
that a coverage depth of 68× gives a false positive rate of
0.110, and this is reported in Figure 5.
The error rates for Illumina GA and ABI SOLiD at maximum
simulated coverage are slightly higher than what was experi-
mentally observed. The additional errors observed in the sim-
ulations are largely associated with low coverage regions and
are different between iterations, whereas the systematic
errors present in the experimental data set at full coverage are
shared between iterations. This shows that the simulation
produces random sampling errors, directly associated with
low coverage regions.
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